Login
$LKFT
$34.79 +$0.81 (2.38%) Live

Ownership

13F as of Q2 2026 · 65.9M shares outstanding

Who owns LKFT?

By type of holder
Institutions 48.4% Everyone else 51.6%

No insider has reported a holding in the last two years, so insiders are counted in "Everyone else".

Concentration Top 10 holders own 71.1%
Gilead Sciences, Inc. 25.4% · Oleg Nodelman 13.2%
Institutional ownership
48.4%
+1.0 pts vs last qtr
Institutional holders
77
-13 vs last qtr
Net shares bought
+642.8K
by institutions in Q2 2026
New / sold out
10 / 23
positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026
  • Madison Avenue Partners, LP +982.6K
  • Prosight Management, LP +493.3K

Sign up to see all 5.

Biggest sellers in Q2 2026
  • Segall Bryant & Hamill, LLC SOLD OUT −426.4K
  • Ameriprise Financial Inc −152.4K

Sign up to see all 5.

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Lakefront Biotherapeutics NV in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2017–FY2025
+33.2%
+5.90% a year
Each share's claim on the business
−24.9%
shrank without buying or selling a share
Spent on buybacks vs paid in stock
— vs €232M
over 6 fiscal years
Diluted shares, split-adjusted
48.0M57.3M66.6M2017: 49.5M shares'172018: 52.1M shares'182022: 65.7M shares'222023: 65.9M shares'232024: 65.9M shares'242025: 65.9M shares'25
Buybacks Stock-based comp
€0€44.3M€88.5M2017 buybacks: €02017 stock comp: €16.5M'172018 buybacks: €02018 stock comp: €26.8M'182022 buybacks: €02022 stock comp: €88.5M'222023 buybacks: €02023 stock comp: €56.7M'232024 buybacks: €02024 stock comp: €19.9M'242025 buybacks: €02025 stock comp: €24.0M'25

How patient are the owners?

Institutional shares by how long they've been held
5+ years10% 3–5 years10% 1–3 years79% Under 1 year1%
Quarterly turnover
5.2%
of institutional shares changed hands
Top 10 managers, median time held
3.3 years

Super Investors

Investment managers reporting LKFT on Form 13F
GS
Gilead Sciences, Inc.
13D · 29.9%
Shares
16.7M
% of company
25.35%
Change vs last qtr
Unchanged
Held since
2024
TC
Tang Capital Management LLC
Shares
3.8M
% of company
5.75%
Change vs last qtr
Unchanged
Held since
2024

28 more super investors behind a free account

See every manager holding Lakefront Biotherapeutics NV, how their position has changed, and how long they've held it.

Sign up free

Institutional Funds

Mutual funds and ETFs reporting LKFT on Form N-PORT; together they hold 2.5% of the company
CO
Columbia Funds Series Trust
Position value
$17M
% of company
0.90%
% of the fund
0.24%
As of
August 31, 2026
IB
Position value
$8.77M
% of company
0.44%
% of the fund
0.10%
As of
June 30, 2026

18 more funds behind a free account

See every fund holding Lakefront Biotherapeutics NV and how much of the fund the position is.

Sign up free

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G
ON
Oleg Nodelman
5%+ holder13D · 13.2%
Shares
8.7M
% of company
13.22%
Change vs last qtr
—
Held since
—
EC
EcoR1 Capital Fund Qualified, L.P.
5%+ holder13D · 12.4%
Shares
8.2M
% of company
12.43%
Change vs last qtr
—
Held since
—

1 more holders behind a free account

See every insider and 5%+ holder of Lakefront Biotherapeutics NV.

Sign up free

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support